Baidu
map

NATURE:薛愿超团队开发RNA-RNA空间相互作用的原位全景分析技术

2020-05-07 MedSci原创 MedSci原创

最近,通过将RNA结合蛋白介导的近距离连接与深度测序相结合,我国研究人员报告了一种RNA原位构象测序(RIC-seq)技术,可以用于全细胞RNA-RNA分子内和分子间相互作用的全局性分析。

具有高级结构的RNA分子通常会相互作用,并与各种RNA结合蛋白结合,以调节关键的生物过程。然而,至今为止,完整细胞中的RNA结构和相互作用在很大程度上仍然是未知的。

最近,通过将RNA结合蛋白介导的近距离连接与深度测序相结合,我国研究人员报告了一种RNA原位构象测序(RIC-seq)技术,可以用于全细胞RNA-RNA分子内和分子间相互作用的全局性分析。

该技术不仅重述了已知的RNA二级结构和三级相互作用,而且还促进了人体细胞中RNA三维(3D)相互作用图谱的生成。

利用这些图谱,研究人员在全细胞范围内识别非编码RNA靶点,并辨别出RNA拓扑域和反式相互作用枢纽。此外,研究人员还发现,增强子和启动子的功能连接性可以利用它们配对相互作用的RNA来分配。

此外,研究人员表明,CCAT1-5L-a,一个超级增强子中枢RNA,与RNA结合蛋白hnRNPK以及来自MYC启动子和增强子的RNA相互作用,通过调节染色质环化来促进MYC转录。

因此,该研究证明了RIC-seq在发现RNA的三维结构、相互作用和调控作用方面的能力和适用性。

 

原始出处:

Zhaokui CaI et al. RIC-seq for global in situ profiling of RNA–RNA spatial interactions, NATURE (2020). 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770819, encodeId=f73d1e7081991, content=<a href='/topic/show?id=061c29449fe' target=_blank style='color:#2F92EE;'>#全景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29449, encryptionId=061c29449fe, topicName=全景)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159438183015, createdName=bioon16, createdTime=Tue Jun 09 06:00:05 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909297, encodeId=330e190929e96, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Nov 23 00:00:05 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884302, encodeId=97ed188430266, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 13 14:00:05 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471659, encodeId=0a2214e1659bb, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 08 23:00:05 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-06-09 bioon16
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770819, encodeId=f73d1e7081991, content=<a href='/topic/show?id=061c29449fe' target=_blank style='color:#2F92EE;'>#全景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29449, encryptionId=061c29449fe, topicName=全景)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159438183015, createdName=bioon16, createdTime=Tue Jun 09 06:00:05 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909297, encodeId=330e190929e96, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Nov 23 00:00:05 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884302, encodeId=97ed188430266, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 13 14:00:05 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471659, encodeId=0a2214e1659bb, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 08 23:00:05 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770819, encodeId=f73d1e7081991, content=<a href='/topic/show?id=061c29449fe' target=_blank style='color:#2F92EE;'>#全景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29449, encryptionId=061c29449fe, topicName=全景)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159438183015, createdName=bioon16, createdTime=Tue Jun 09 06:00:05 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909297, encodeId=330e190929e96, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Nov 23 00:00:05 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884302, encodeId=97ed188430266, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 13 14:00:05 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471659, encodeId=0a2214e1659bb, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 08 23:00:05 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2021-02-13 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1770819, encodeId=f73d1e7081991, content=<a href='/topic/show?id=061c29449fe' target=_blank style='color:#2F92EE;'>#全景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29449, encryptionId=061c29449fe, topicName=全景)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=159438183015, createdName=bioon16, createdTime=Tue Jun 09 06:00:05 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909297, encodeId=330e190929e96, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Mon Nov 23 00:00:05 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884302, encodeId=97ed188430266, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 13 14:00:05 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471659, encodeId=0a2214e1659bb, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri May 08 23:00:05 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 ylz8405

相关资讯

Nat Biot:液体活检新突破!科学家们开发出“RNA测序”的通用模板

通过检测血液或尿液中少量的RNA来诊断或治疗疾病是一个新兴领域。随着技术的进步,研究人员可以对RNA片段进行测序,但不同的人使用不同的方法来测序RNA,有时会得到不同的结果,这是影响成功的一个重大障碍,使得此领域很难取得进展。近来,密歇根大学Tewari教授的实验室领导了美国和荷兰的9个实验室组成联盟,通过美国国立卫生研究院,试图解决这个问题。该联盟测试了9种不同的RNA测序方法,以了解和标准化测

Nature Methods:MIT开发出便携、低成本的单细胞RNA测序新手段

每个细胞的基因表达谱随其功能而异。从血液或组织样本中的许多单个细胞中提取RNA可以根据基因表达模式区分细胞。这使科学家有机会确定细胞功能,包括它们在疾病中的作用或对治疗的反应。

Cell:单细胞RNA测序为果蝇神经元分类

大脑的神经系统由成千上万种不同类型的神经细胞构成,这些神经细胞在细胞形态,突触连结及生理功能上具有高度的多样性。不同种类的神经细胞中,其基因组、蛋白组、化学分子组成、代谢也都有着很大的差别。因此,对脑内神经细胞进行分类,以更好地理解其分子特性及生理功能十分重要。

Genome Res:RNA测序技术发现胶质瘤新的分子分型特征

生命科学学院生物动态光学成像中心(BIOPIC)苏晓东研究组和北京天坛医院江涛研究组以及加州大学圣地亚哥分校的Clark Chen研究组合作在《Genome Research》杂志在线发表了题为“RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary gliobl

Sci Rep:在克兰费尔特综合征中,miRNA的表达量减少

在男性克兰费尔特综合征(KS)中,多种类型的表型谱和症状的不同严重度表明了表观遗传调控因子在其中具有作用。因此,最近有研究人员进行了旨在评估miRNAs在KS的临床表现中可能的参与情况。研究人员在10名非马赛克KS病人中,对其外周血单核细胞(PBMCs)进行了转录组分析,并且还包括了10名年龄相匹配的健康男性和10名年龄匹配的健康女性对照,且具有正常的核型。研究人员从PBMC中进行了RNA提取并构

RNA测序有助于遗传病的诊断

美国人类遗传学学会(ASHG)的年会于上周在圣地亚哥举行。会上公布的一项新研究表明,RNA测序有助于提高外显子组和基因组测序的遗传病诊断率。

Baidu
map
Baidu
map
Baidu
map